11/7/2018 | CAHYLM | Bausch Health tenders, solicits consents for 7½% notes due 2021
|
6/1/2018 | CAHYLM | Valeant to redeem 5 3/8%, 6 3/8%, 6¾%, 7¼% senior notes on July 2
|
5/8/2018 | BKBWCAHYLM | Valeant cuts debt by $6.9 billion since 2016; ‘more work to be done’
|
4/12/2018 | CAHYLM | Valeant plans to redeem $150 million 6 3/8% senior notes on May 14
|
4/10/2018 | CAHYLM | Valeant Pharmaceuticals wraps tender offers for three series of notes
|
3/26/2018 | CAHYLM | Valeant receives early tenders for $1.45 billion notes, to buy all
|
3/12/2018 | CAHYLM | Valeant, unit up tender for 6 3/8%, 5 3/8%, 6¾% notes to $1.5 billion
|
3/12/2018 | CAHYLM | Valeant, unit tender for $1.25 billion of 6 3/8%, 5 3/8%, 6¾% notes
|
2/28/2018 | CAHYLM | Valeant Pharmaceuticals calls $71 million 7% senior notes due 2020
|
12/15/2017 | HYLM | Valeant gives early tender results, increases subcap for 5 3/8% notes
|
12/4/2017 | CAHYLM | Valeant offers to buy back up to $1.5 billion 7%, 6 3/8%, 5 3/8% notes
|
12/4/2017 | CAHYLM | Valeant, unit begin month-long tender for $1 billion of three issues
|
10/16/2017 | CAHYLM | Valeant tenders for $1 billion notes oversubscribed at early deadline
|
10/2/2017 | CAHYLM | Valeant Pharmaceuticals tenders for $1 billion of three note series
|
7/13/2017 | CAHYLM | Valeant to call $500 million of 6¾% notes due 2018 on Thursday
|
3/21/2017 | CAHYLM | Valeant accepts 70.9% of tendered 6¾% notes in oversubscribed offer
|
3/10/2017 | CAHYLM | Valeant lifts tender offer cap for 6¾% notes due 2018 to $1.1 billion
|
3/7/2017 | CAHYLM | Valeant begins tender offer for up to $600 million 6¾% notes due 2018
|
11/15/2016 | BKBWCADDHYLM | Valeant aims to pay $5 billion of $30 billion debt via asset sales
|
8/9/2016 | BKBWCAHYLM | Valeant says debt-cutting remains a focus, $880 million cut since Q1, seeks covenant relief
|
6/7/2016 | BKBWHYLM | Valeant liquidity ‘solid,’ committed to $1.7 billion debt reduction
|
4/1/2015 | CVLM | Salix convertible noteholders get change-of-control put option
|
4/1/2015 | CAHYLM | Valeant to redeem Salix’s 6% senior notes due 2021 in two stages
|
1/15/2015 | CAHYLM | Valeant Pharmaceuticals calls $499.58 million 6 7/8% notes in full
|
1/8/2015 | BKBWCAHYLMLW | Valeant cuts leverage to 3.5x, holds out prospect of more debt paydowns
|
12/1/2014 | HYLM | Valeant Pharmaceuticals calls $445 million 6 7/8% senior notes due 2018
|
11/20/2014 | HYLM | Valeant to buy back up to $2 billion of notes under repurchase program
|
9/15/2014 | HYLM | Valeant calls in full $500 million 6¾% notes for Oct. 15 redemption
|
1/7/2014 | BKHYLM | Valeant Pharmaceuticals reiterates 2013 guidance, eyes 40% increase in 2014
|
12/2/2013 | HYLM | Valeant Pharmaceuticals calls remaining $465.5 million 61/2% notes
|
11/15/2013 | HYLM | Valeant calls $450 million 61/2% notes due 2016 via new issue proceeds
|
11/15/2013 | HYLM | Valeant plans to call 61/2% senior notes due 2016 via new issue proceeds
|
11/19/2012 | CVLM | Valeant buys back C$2.4 million 5.375% convertibles for C$7.9 million
|
11/19/2012 | CAHYLM | Valeant buys back C$89.9 million three senior note series at discount
|
11/3/2011 | CACVHYLM | Valeant Pharmaceuticals reports double-digit growth, ends Q3 with $5.6 billion of debt
|
11/3/2011 | CACVHYLM | Valeant resumes buyback program for convertibles, notes and other debt
|
9/15/2011 | CACVHYLM | Valeant eyes growth in Europe; cash flow from operations could hit $900 million in 2012
|
8/29/2011 | CACVHYLM | Valeant increases securities repurchase program to C$1.8 billion
|
5/9/2011 | CVLM | Valeant buys back $63.8 million 5.375% convertibles in first quarter
|
4/20/2011 | CVLM | Valeant issues call to redeem all 4% convertible notes due 2013
|
2/28/2011 | CVLM | Valeant buys back $137.6 million of convertibles, 2.3 million shares
|
11/4/2010 | CACVHYLM | Valeant to buy back $1.5 billion convertibles, senior notes, stock
|